Desk
Clinical, biotech, and health-system AI.
The most promising healthcare AI here isn't a chatbot but a chart reader that stays inside the hospital, leaves the decisions to clinicians and turns years of review into usable evidence.
Google Cloud’s new healthcare agent, in preview, connects to health records, billing systems and Medicare data to handle records synthesis and prior authorization. It sells to both providers and insurers, so human review of denials is the safeguard that matters.
Strip away the gossip and the Nvidia scandal comes down to a short list of confirmed facts, a long list of open questions, and a company line that has not settled anything.
NVIDIA opens DSX OS — AICR, NVCRE, and NVSentinel — so GPU Kubernetes clusters get reproducible recipes, workload certification, and continuous health loops instead of hope-based handovers.
Anima's clinic numbers make a strong case that AI's best healthcare role is clearing the queues where patients get lost, as long as clinicians stay the final check.
Microsoft's diagnostic AI beat generalist doctors on hard cases in a peer-reviewed simulation, but the real test starts now in a Boston emergency department.
An investment research firm and Anthropic ran a genuinely interesting autonomous protein-design experiment, then sold it as drug discovery. The science got the easy part; the marketing skipped the hard part.
Carbon-X lets researchers ask DNA questions in plain English on their own laptops, a smart privacy design, but its predictions have not been checked against a single wet-lab experiment yet.
A federal judge ended Ann Altman's abuse lawsuit against her brother on procedural grounds, which closes the case in court without ever answering the question at its center.
OpenAI is buying a drug-program coordination platform, betting that the slowest part of medicine isn't only the science but the logistics around it. That's a smart target, with stakes to match.
Anthropic's usage-policy rewrite targets election interference, weapons and surveillance. The line that will get the attention, though, bans 'needless' cruelty toward Claude itself.
Rival AI companies and two federal agencies are pooling money and data behind one nonprofit's virtual cell, a bet that biology's real bottleneck is shared data, not smarter models.